Neostigmine Methylsulphate Fresenius ( )
[3-(Dimethylcarbamoyloxy)phenyl]-trimethylazanium
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 4456.
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Fresenius Kabi Manufacturing SA (Pty) Ltd | Neostigmine methylsulphate fresenius ( ), Neostigmine methylsulphate ( ) fresenius | 0,5 mg/1 ml, 2,5 mg/1 ml | C0907, W0260 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Neostigmine methylsulphate fresenius 0,5 mg/1 ML (ampoules) EACH 1,0 ml SOLUTION CONTAINS NEOSTIGMINE METHYLSULPHATE A 0,5 mg | 0,5 mg/1 ml(Ampoules) | C0907 | Old Medicine | Not determined | None |
| Neostigmine methylsulphate 2,5 mg/1 ML (ampoules) fresenius EACH 1 ml AMPOULE CONTAINS NEOSTIGMINE METHYLSULPHATE 2,5 mg | 2,5 mg/1 ml(Ampoules) | W0260W/5.3/260 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.